JPWO2021202977A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202977A5 JPWO2021202977A5 JP2022556491A JP2022556491A JPWO2021202977A5 JP WO2021202977 A5 JPWO2021202977 A5 JP WO2021202977A5 JP 2022556491 A JP2022556491 A JP 2022556491A JP 2022556491 A JP2022556491 A JP 2022556491A JP WO2021202977 A5 JPWO2021202977 A5 JP WO2021202977A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- optionally substituted
- disease
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 98
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 44
- 230000004154 complement system Effects 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 230000002159 abnormal effect Effects 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims description 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000016323 C3 glomerulonephritis Diseases 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 4
- 208000002557 hidradenitis Diseases 0.000 claims description 4
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000028185 Angioedema Diseases 0.000 claims description 3
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 3
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 3
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 208000035894 Immune-mediated necrotising myopathy Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 3
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 3
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000027073 Stargardt disease Diseases 0.000 claims description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 208000005707 acquired angioedema Diseases 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 3
- 206010011005 corneal dystrophy Diseases 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000024908 graft versus host disease Diseases 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 208000012101 immune-mediated necrotizing myopathy Diseases 0.000 claims description 3
- 208000018351 immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 3
- 231100000855 membranous nephropathy Toxicity 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 125000003003 spiro group Chemical group 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- -1 2-pyridinyl Chemical group 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 2
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000007917 background diabetic retinopathy Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 201000000159 corneal neovascularization Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 201000011190 diabetic macular edema Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 39
- 230000001594 aberrant effect Effects 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 206010014568 Empyema Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004799P | 2020-04-03 | 2020-04-03 | |
| US63/004,799 | 2020-04-03 | ||
| PCT/US2021/025547 WO2021202977A1 (fr) | 2020-04-03 | 2021-04-02 | Pyrrolopyrimidine amines en tant qu'inhibiteurs du complément |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519824A JP2023519824A (ja) | 2023-05-15 |
| JPWO2021202977A5 true JPWO2021202977A5 (fr) | 2024-05-02 |
Family
ID=77929437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556491A Pending JP2023519824A (ja) | 2020-04-03 | 2021-04-02 | 補体阻害剤としてのピロロピリミジンアミン |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230159536A1 (fr) |
| EP (1) | EP4125914A4 (fr) |
| JP (1) | JP2023519824A (fr) |
| KR (1) | KR20220163955A (fr) |
| CN (1) | CN115427044A (fr) |
| AR (1) | AR121715A1 (fr) |
| AU (1) | AU2021246098A1 (fr) |
| BR (1) | BR112022018067A2 (fr) |
| CA (1) | CA3176808A1 (fr) |
| CL (1) | CL2022002649A1 (fr) |
| CO (1) | CO2022015630A2 (fr) |
| CR (1) | CR20220553A (fr) |
| CU (1) | CU20220060A7 (fr) |
| DO (1) | DOP2022000211A (fr) |
| EC (1) | ECSP22085221A (fr) |
| IL (1) | IL296978A (fr) |
| JO (1) | JOP20220227A1 (fr) |
| MX (1) | MX2022012056A (fr) |
| PE (1) | PE20230601A1 (fr) |
| TW (1) | TW202204358A (fr) |
| UY (1) | UY39150A (fr) |
| WO (1) | WO2021202977A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3234428A1 (fr) * | 2021-10-18 | 2023-04-27 | Nader Najafian | Utilisation d'un inhibiteur du facteur d du complement pour le traitement de la nephropathie lupique et de la nephropathie a immunoglobulines a |
| WO2024008121A1 (fr) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | Composés azabicyclo difluoro-substitués et leurs utilisations |
| WO2024047078A1 (fr) * | 2022-09-01 | 2024-03-07 | F. Hoffmann-La Roche Ag | Régime posologique de vicasinabine |
| US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
| US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| BR112013017316A2 (pt) * | 2011-01-04 | 2019-09-24 | Novartis Ag | compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd) |
-
2021
- 2021-03-31 AR ARP210100817A patent/AR121715A1/es unknown
- 2021-04-01 TW TW110112139A patent/TW202204358A/zh unknown
- 2021-04-02 KR KR1020227033595A patent/KR20220163955A/ko active Search and Examination
- 2021-04-02 MX MX2022012056A patent/MX2022012056A/es unknown
- 2021-04-02 BR BR112022018067A patent/BR112022018067A2/pt unknown
- 2021-04-02 JP JP2022556491A patent/JP2023519824A/ja active Pending
- 2021-04-02 EP EP21781014.2A patent/EP4125914A4/fr active Pending
- 2021-04-02 PE PE2022002121A patent/PE20230601A1/es unknown
- 2021-04-02 IL IL296978A patent/IL296978A/en unknown
- 2021-04-02 CU CU2022000060A patent/CU20220060A7/es unknown
- 2021-04-02 CR CR20220553A patent/CR20220553A/es unknown
- 2021-04-02 JO JOP/2022/0227A patent/JOP20220227A1/ar unknown
- 2021-04-02 AU AU2021246098A patent/AU2021246098A1/en active Pending
- 2021-04-02 CA CA3176808A patent/CA3176808A1/fr active Pending
- 2021-04-02 CN CN202180025930.0A patent/CN115427044A/zh active Pending
- 2021-04-02 WO PCT/US2021/025547 patent/WO2021202977A1/fr active Application Filing
- 2021-04-02 US US17/915,179 patent/US20230159536A1/en active Pending
- 2021-04-05 UY UY0001039150A patent/UY39150A/es unknown
-
2022
- 2022-09-28 DO DO2022000211A patent/DOP2022000211A/es unknown
- 2022-09-28 CL CL2022002649A patent/CL2022002649A1/es unknown
- 2022-10-31 CO CONC2022/0015630A patent/CO2022015630A2/es unknown
- 2022-11-02 EC ECSENADI202285221A patent/ECSP22085221A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296978A (en) | Pyrrolopyrimidines are reliable as complement inhibitors | |
| KR100530297B1 (ko) | 옥사졸리디논의 제조 방법 | |
| JP6633539B2 (ja) | ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換−ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程 | |
| JP2001520645A (ja) | 新規な化合物 | |
| JPWO2021202977A5 (fr) | ||
| JP2015515976A5 (fr) | ||
| JP2018515581A5 (fr) | ||
| JP2017508733A5 (fr) | ||
| TWI297687B (en) | Linezolid-crystal form ii | |
| JP2009534405A5 (fr) | ||
| IL305879A (en) | Benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors are converted | |
| JP2018531218A5 (fr) | ||
| EP1831231A1 (fr) | Ligands de recepteur nicotinique d'acetylcholine | |
| JP2004091369A (ja) | 新規ビフェニル化合物 | |
| JPS62502046A (ja) | セファロスポリン中間体の製法 | |
| JPS60158192A (ja) | 殺菌・殺カビ性イミダゾール及びトリアゾール | |
| IL96811A (en) | Transformed history of oxazole thiazole oxadiazole and thiaziazole preparation and pharmaceutical preparations containing them | |
| SI9300075A (en) | 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2a)pyrimidin-4-ones, pharmaceutical preparations comprising the same and process pro their preparing | |
| CA2549954A1 (fr) | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxamide, leur preparation et leur application en therapeutique | |
| JP2013544880A5 (fr) | ||
| JPH0249787A (ja) | チエノトリアゾロジアゼピン化合物およびその医薬用途 | |
| JPWO2019195720A5 (fr) | ||
| JPWO2021155317A5 (fr) | ||
| JPWO2020163544A5 (fr) | ||
| JP2006523640A (ja) | 置換７−アザ−キナゾリン化合物 |